Preview

Kutafin Law Review

Advanced search

Genome-Editing Technologies in Biomedical Research: The Regulatory Conditions for the Development

https://doi.org/10.17803/2313-5395.2021.1.15.115-128

Full Text:

Abstract

Significant progress has been made in the development of genetic technologies in recent decades. Currently, high-performance sequencing and, most importantly, genome editing technologies are widely used and available for laboratories in Russia. Existing technologies are not without drawbacks that significantly hinder further development, in addition, all the necessary reagents and materials, as well as equipment, are produced exclusively abroad. The review highlights the international experience of using genome editing technologies for the treatment and prevention of genetic diseases, vector-borne and viral infections, it offers recommendations for the development of this area in the Russian Federation. Attention is drawn to the legal and ethical regulation, mainly at the level of basic principles. The conclusion is formulated on the need for accelerated adaptation of basic ethical and legal principles for genome editing activities in scientific biomedical activities.

About the Authors

A. A. Chaplenko
First Moscow State Medical University (Sechenov University)
Russian Federation

Alexander A. Chaplenko - Cand. Sci., Associate Professor, Department of Organization and Management in the Field of Drugs Circulation, First Moscow State Medical University (Sechenov University).

Bolshaya Pirogovskaya St., 2, build. 4, Moscow, 119435.



A. A. Mokhov
Kutafin Moscow State Law University (MSAL)
Russian Federation

Alexander A. Mokhov - Dr. Sci. (Law), Professor, Head of the Department of Medical Law, Kutafin Moscow State Law University (MSAL).

Sadovaya-Kudrinskaya St., 9, Moscow, 125993.



A. N. Yavorsky
Pushchino State Institute of Natural Science
Russian Federation

Alexander N. Yavorsky - Dr. Sci. (Medicine), Professor, Chief Researcher, Pushchino State Institute of Natural Science.

Nauki Av., 3, Pushchino, Moscow Region, 142290.



References

1. Anzalone, A., Koblan, L. and Liu, D., (2020). Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nature Biotechnology, 38(7), pp. 824-844.

2. Bischoff, N., Wimberger, S., Maresca, M. and Brakebusch, C., (2020). Improving Precise CRISPR Genome Editing by Small Molecules: Is there a Magic Potion? Cells, 9(5), p. 1318.

3. Brinkman, E., Chen, T., de Haas, M., Holland, H., Akhtar, W. and van Steensel, B., (2018). Kinetics and Fidelity of the Repair of Cas9-Induced Double-Strand DNA Breaks. Molecular Cell, 70(5), pp. 801-813.e6.

4. Brokowski, C. and Adli, M., (2019). CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool. Journal of Molecular Biology, 431(1), pp. 88-101.

5. Chen, K. and Knoepfler, P., (2016). To CRISPR and beyond: the evolution of genome editing in stem cells. Regenerative Medicine, 11(8), pp. 801-816.

6. Chuai, G., Ma, H., Yan, J., Chen, M., Hong, N., Xue, D., Zhou, C., Zhu, C., Chen, K., Duan, B., Gu, F., Qu, S., Huang, D., Wei, J. and Liu, Q., (2018). DeepCRISPR: optimized CRISPR guide RNA design by deep learning. Genome Biology, 19(1).

7. Cribbs, A. and Perera, S., (2017). Science and bioethics of CRISPR-CAS9 gene editing: An analysis towards separating facts and fiction. Yale Journal of Biology and Medicine, 90(4), pp. 625-634.

8. Cyranoski, D., (2019). Russian ‘CRISPR-baby' scientist has started editing genes in human eggs with goal of altering deaf gene. Nature, 574(7779), pp. 465-466.

9. Dyikanov, D., Vasiluev, P., Rysenkova, K., Aleksandrushkina, N., Tyurin-Kuzmin, P., Kulebyakin, K., Rubtsov, Y., Shmakova, A., Evseeva, M., Balatskiy, A., Semina, E., Rostovtseva, A., Makarevich, P. and Karagyaur, M., (2019). Optimization of CRISPR/Cas9 Technology to Knock Out Genes of Interest in Aneuploid Cell Lines. Tissue Engineering. Part C: Methods, 25(3), pp. 168-175.

10. Eid, A., Alshareef, S. and Mahfouz, M., (2018). CRISPR base editors: genome editing without double-stranded breaks. Biochemical Journal, 475(11), pp. 1955-1964.

11. Gerace, D., Martiniello-Wilks, R., Nassif, N., Lal, S., Steptoe, R. and Simpson, A., (2017). CRISPR-targeted genome editing of mesenchymal stem cell-derived therapies for type 1 diabetes: a path to clinical success? Stem Cell Research & Therapy, 8(1).

12. Germini, D., Tsfasman, T., Zakharova, V., Sjakste, N., Lipinski, M. and Vassetzky, Y., (2018). A Comparison of Techniques to Evaluate the Effectiveness of Genome Editing. Trends in Biotechnology, 36(2), pp. 147-159.

13. Greely, H., (2019). CRISPR'd babies: human germline genome editing in the ‘He Jiankui affair'. Journal of Law and the Biosciences, 6(1), pp. 111-183.

14. Hackett, J., Huang, Y., Gunesdogan, U., Gretarsson, K., Kobayashi, T. and Surani, M., (2018). Tracing the transitions from pluripotency to germ cell fate with CRISPR screening. Nature Communications, 9(1).

15. Hua, Y., Wang, C., Huang, J. and Wang, K., (2017). A simple and efficient method for CRISPR/Cas9-induced mutant screening. Journal of Genetics and Genomics, 44(4), pp. 207-213.

16. Karagyaur, M., Rubtsov, Y., Vasiliev, P. and Tkachuk, V., (2018). Practical Recommendations for Improving Efficiency and Accuracy of the CRISPR/Cas9 Genome Editing System. Biochemistry (Moscow), 83(6), pp. 629-642.

17. Khokhlov, A., Chudova, N. and Tsyzman, L., (2018). The results of the analysis of the expert work of the Council on Ethics of the Ministry of Health of the Russian Federation. Meditsinskaya Etika, 2, pp. 17-22. (In Russ.).

18. Kick, L., Kirchner, M. and Schneider, S., (2017). CRISPR-Cas9: From a bacterial immune system to genome-edited human cells in clinical trials. Bioengineered, 8(3), pp. 280-286.

19. Koonin, E., Makarova, K. and Zhang, F., (2017). Diversity, classification and evolution of CRISPR-Cas systems. Current Opinion in Microbiology, 37, pp. 67-78.

20. Lee, J., Jeong, E., Lee, J., Jung, M., Shin, E., Kim, Y., Lee, K., Jung, I., Kim, D., Kim, S. and Kim, J., (2018). Directed evolution of CRISPR-Cas9 to increase its specificity. Nature Communications, 9(1).

21. Li, G., Zhang, X., Zhong, C., Mo, J., Quan, R., Yang, J., Liu, D., Li, Z., Yang, H. and Wu, Z., (2017). Small molecules enhance CRISPR/ Cas9-mediated homology-directed genome editing in primary cells. Scientific Reports, 7(1).

22. Liu, Z., Chen, S., Jin, X., Wang, Q., Yang, K., Li, C., Xiao, Q., Hou, P., Liu, S., Wu, S., Hou, W., Xiong, Y., Kong, C., Zhao, X., Wu, L., Li, C., Sun, G. and Guo, D., (2017). Genome editing of the HIV coreceptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection. Cell & Bioscience, 7(1).

23. Logunov, D., Dolzhikova, I., Zubkova, O., Tukhvatulin, A., Shcheblyakov, D., Dzharullaeva, A., Grousova, D., Erokhova, A., Kovyrshina, A., Botikov, A., Izhaeva, F., Popova, O., Ozharovskaya, T., Esmagambetov, I., Favorskaya, I., Zrelkin, D., Voronina, D., Shcherbinin, D., Semikhin, A., Simakova, Y., Tokarskaya, E., Lubenets, N., Egorova, D., Shmarov, M., Nikitenko, N., Morozova, L., Smolyarchuk, E., Kryukov, E., Babira, V., Borisevich, S., Naroditsky, B. and Gintsburg, A., (2020). Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet, 396(10255), pp. 887-897.

24. Long, L., Guo, D., Gao, W., Yang, W., Hou, L., Ma, X., Miao, Y., Botella, J. and Song, C., (2018). Optimization of CRISPR/Cas9 genome editing in cotton by improved sgRNA expression. Plant Methods, 14(1).

25. Lucibello, F., Menegatti, S. and Menger, L., (2020). Methods to edit T cells for cancer immunotherapy. Methods in Enzymology, 631, pp. 107-135.

26. Mokhov, А., Levushkin, А. and Yavorsky, A., (2020). Genome Editing of Human Embryo: Allow or Prohibit? Journal of Advanced Research in Law and Economics, 11(2), p. 483. (In Russ.).

27. Mokhov, A. and Yavorsky, A., (2020). High-Tech Ethics: Establishment Issues and Development Prospects. Jurist, 12, pp. 2-8. (In Russ.).

28. NobelPrize.org. 2021. The Nobel Prize in Chemistry 2020. [online] Available at: https://www.nobelprize.org/prizes/chemistry/2020/press-release [Accessed 22.03. 2021].

29. Paix, A., Folkmann, A., Goldman, D., Kulaga, H., Grzelak, M., Rasoloson, D., Paidemarry, S., Green, R., Reed, R. and Seydoux, G., (2017). Precision genome editing using synthesis-dependent repair of Cas9-induced DNA breaks. Proceedings of the National Academy of Sciences, 114(50), pp. E10745-E10754.

30. Rebrikov, D., (2021). Human genome editing. Bulletin of RSMU, 3, pp. 4-14.

31. Rulten, S. and Grundy, G., (2017). Non-homologous end joining: Common interaction sites and exchange of multiple factors in the DNA repair process. BioEssays, 39(3), p. 1600209.

32. Vitelli, V., Galbiati, A., Iannelli, F., Pessina, F., Sharma, S. and d'Adda di Fagagna, F., (2017). Recent Advancements in DNA DamageTranscription Crosstalk and High-Resolution Mapping of DNA Breaks. Annual Review of Genomics and Human Genetics, 18(1), pp. 87-113.

33. Wang, X., Lee, B. and Zha, S., (2020). The recent advances in non-homologous end-joining through the lens of lymphocyte development. DNA Repair, 94, p. 102874.

34. You, L., Tong, R., Li, M., Liu, Y., Xue, J. and Lu, Y., (2019). Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research. Molecular Therapy — Methods & Clinical Development, 13, pp. 359-370.

35. Zischewski, J., Fischer, R. and Bortesi, L., (2017). Detection of on-target and off-target mutations generated by CRISPR/Cas9 and other sequence-specific nucleases. Biotechnology Advances, 35(1), pp. 95-104.


For citation:


Chaplenko A.A., Mokhov A.A., Yavorsky A.N. Genome-Editing Technologies in Biomedical Research: The Regulatory Conditions for the Development. Kutafin Law Review. 2021;8(1):115-128. https://doi.org/10.17803/2313-5395.2021.1.15.115-128

Views: 14


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2313-5395 (Print)
ISSN 2410-2059 (Online)